flutamide has been researched along with Injuries, Radiation in 7 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the effectiveness of palladium 103 (Pd-103) brachytherapy in Stage T1 and T2 adenocarcinoma of the prostate." | 7.70 | Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients. ( Behar, RJ; Cantor, A; Chovnick, SD; Huff, W; Otheguy, J; Perez, R; Sharkey, J; Solc, Z, 1998) |
| "To assess the effectiveness of palladium 103 (Pd-103) brachytherapy in Stage T1 and T2 adenocarcinoma of the prostate." | 3.70 | Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients. ( Behar, RJ; Cantor, A; Chovnick, SD; Huff, W; Otheguy, J; Perez, R; Sharkey, J; Solc, Z, 1998) |
| "The erythema is an effect of radiotherapy treatment in breast cancer patients." | 2.73 | Comparison of three instrumental methods for the objective evaluation of radiotherapy induced erythema in breast cancer patients and a study of the effect of skin lotions. ( Franzén, L; Geladi, P; Larson, J; Lindholm-Sethson, B; Nyström, J; Svensk, AC, 2007) |
| " This technique has been used most commonly to treat prostate cancers in combination with hormonal therapy." | 2.42 | Rotational 3D-conformal radiation therapy (conformation therapy) combined with hormone therapy for the treatment of stage B2/C prostate cancer in Japanese men. ( Igaki, H; Kaizu, T; Karasawa, K; Matsuda, T; Niibe, Y; Shinohara, M; Tanaka, Y, 2003) |
| "To evaluate the severity of genitourinary (GU) toxicity in high-dose-rate (HDR) brachytherapy combined with hypofractionated external beam radiotherapy (EBRT) for prostate cancer and to explore factors that might affect the severity of GU toxicity." | 1.35 | Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy ( Baba, S; Hayakawa, K; Ishiyama, H; Kitano, M; Kotani, S; Matsumoto, K; Okusa, H; Satoh, T; Tabata, K; Uemae, M, 2009) |
| "The toxicity rates of 480 consecutive prostate cancer patients were reviewed and compared using the chi2 test." | 1.33 | Impact of hormone therapy on acute radiotherapy toxicity in the treatment of prostate cancer. ( Gratzle, J; Jani, AB; Myers, M, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishiyama, H | 1 |
| Kitano, M | 1 |
| Satoh, T | 1 |
| Kotani, S | 1 |
| Uemae, M | 1 |
| Matsumoto, K | 1 |
| Okusa, H | 1 |
| Tabata, K | 1 |
| Baba, S | 1 |
| Hayakawa, K | 1 |
| Karasawa, K | 1 |
| Kaizu, T | 1 |
| Niibe, Y | 1 |
| Igaki, H | 1 |
| Shinohara, M | 1 |
| Tanaka, Y | 1 |
| Matsuda, T | 1 |
| Jani, AB | 2 |
| Gratzle, J | 2 |
| Myers, M | 1 |
| Lawton, CA | 1 |
| Bae, K | 1 |
| Pilepich, M | 1 |
| Hanks, G | 1 |
| Shipley, W | 1 |
| Nyström, J | 1 |
| Svensk, AC | 1 |
| Lindholm-Sethson, B | 1 |
| Geladi, P | 1 |
| Larson, J | 1 |
| Franzén, L | 1 |
| Sharkey, J | 1 |
| Chovnick, SD | 1 |
| Behar, RJ | 1 |
| Perez, R | 1 |
| Otheguy, J | 1 |
| Solc, Z | 1 |
| Huff, W | 1 |
| Cantor, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A PHASE III TRIAL OF THE USE OF LONG TERM TOTAL ANDROGEN SUPPRESSION FOLLOWING NEOADJUVANT HORMONAL CYTOREDUCTION AND RADIOTHERAPY IN LOCALLY ADVANCED CARCINOMA OF THE PROSTATE[NCT00767286] | Phase 3 | 0 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for flutamide and Injuries, Radiation
| Article | Year |
|---|---|
Rotational 3D-conformal radiation therapy (conformation therapy) combined with hormone therapy for the treatment of stage B2/C prostate cancer in Japanese men.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Ch | 2003 |
2 trials available for flutamide and Injuries, Radiation
| Article | Year |
|---|---|
Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Follow-Up Studies; | 2008 |
Comparison of three instrumental methods for the objective evaluation of radiotherapy induced erythema in breast cancer patients and a study of the effect of skin lotions.
Topics: Aloe; Breast Neoplasms; Dose-Response Relationship, Radiation; Electrons; Erythema; Female; Flutamid | 2007 |
4 other studies available for flutamide and Injuries, Radiation
| Article | Year |
|---|---|
Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Brachytherapy; Flutamide; Humans; | 2009 |
Impact of hormone therapy on acute radiotherapy toxicity in the treatment of prostate cancer.
Topics: Aged; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Brachytherapy; Cohort Studie | 2005 |
Late radiotherapy toxicity after prostate cancer treatment: influence of hormonal therapy.
Topics: Aged; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Gastrointestinal Diseases; Goserelin; Hu | 2005 |
Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Ambulatory Care; Androgen Antagonists; Antineoplastic Agent | 1998 |